The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting

Francesco Benedetti, Cristina Colombo, Adele Pirovano, Elena Marino, Enrico Smeraldi

Research output: Contribution to journalArticle

Abstract

Rationale: The noradrenergic and dopaminergic systems are targets for antidepressants and are stimulated by serotonergic antidepressant drugs. The COMT enzyme inactivates catecholamines, and the COMT Val(108/158)Met polymorphism (rs4680) influences the enzyme activity. Clinical studies on the effect of rs4680 on antidepressant response gave contrasting results. Objectives: We studied the effect of rs4680 on response to paroxetine antidepressant monotherapy at doses administered upon clinical need. Materials and methods: Fifty-five consecutively referred outpatients affected by a major depressive episode without psychotic features in course of major depressive disorder were administered paroxetine at a mean daily dose of 31.64 mg for 1 month. Changes in severity of depression were assessed with weekly Hamilton depression ratings and analyzed with repeated measures analysis of variance in the context of general linear model, taking into account potential confounding variables (age, sex, number of previous illness episodes, duration of current episode and paroxetine daily dose). Results: rs4680 significantly interacted with time in affecting antidepressant response to paroxetine, with outcome being inversely proportional to the enzyme activity: better effects in Met/Met homozygotes, worse effects in Val/Val homozygotes and intermediate effects in heterozygotes. The effect became significant at the third week of treatment. Paroxetine daily dose was proportional to baseline severity, but did not influence outcome. Conclusions: This is the first study that reports a positive effect of rs4680 on response to selective serotonin reuptake inhibitors monotherapy in a Caucasian sample. Our findings support the hypothesis that factors affecting catecholaminergic neurotransmission might contribute to shape the individual response to antidepressants.

Original languageEnglish
Pages (from-to)155-160
Number of pages6
JournalPsychopharmacology
Volume203
Issue number1
DOIs
Publication statusPublished - Mar 2009

Fingerprint

Catechol O-Methyltransferase
Paroxetine
Antidepressive Agents
Homozygote
Enzymes
Depression
Serotonin Agents
Confounding Factors (Epidemiology)
Major Depressive Disorder
Serotonin Uptake Inhibitors
Heterozygote
Synaptic Transmission
Catecholamines
Linear Models
Analysis of Variance
Outpatients

Keywords

  • Antidepressant
  • COMT
  • Dopamine
  • Noradrenaline
  • Paroxetine
  • Serotonin

ASJC Scopus subject areas

  • Pharmacology

Cite this

The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting. / Benedetti, Francesco; Colombo, Cristina; Pirovano, Adele; Marino, Elena; Smeraldi, Enrico.

In: Psychopharmacology, Vol. 203, No. 1, 03.2009, p. 155-160.

Research output: Contribution to journalArticle

@article{cfa6a8df48b1412b850ef659b12d7bc6,
title = "The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting",
abstract = "Rationale: The noradrenergic and dopaminergic systems are targets for antidepressants and are stimulated by serotonergic antidepressant drugs. The COMT enzyme inactivates catecholamines, and the COMT Val(108/158)Met polymorphism (rs4680) influences the enzyme activity. Clinical studies on the effect of rs4680 on antidepressant response gave contrasting results. Objectives: We studied the effect of rs4680 on response to paroxetine antidepressant monotherapy at doses administered upon clinical need. Materials and methods: Fifty-five consecutively referred outpatients affected by a major depressive episode without psychotic features in course of major depressive disorder were administered paroxetine at a mean daily dose of 31.64 mg for 1 month. Changes in severity of depression were assessed with weekly Hamilton depression ratings and analyzed with repeated measures analysis of variance in the context of general linear model, taking into account potential confounding variables (age, sex, number of previous illness episodes, duration of current episode and paroxetine daily dose). Results: rs4680 significantly interacted with time in affecting antidepressant response to paroxetine, with outcome being inversely proportional to the enzyme activity: better effects in Met/Met homozygotes, worse effects in Val/Val homozygotes and intermediate effects in heterozygotes. The effect became significant at the third week of treatment. Paroxetine daily dose was proportional to baseline severity, but did not influence outcome. Conclusions: This is the first study that reports a positive effect of rs4680 on response to selective serotonin reuptake inhibitors monotherapy in a Caucasian sample. Our findings support the hypothesis that factors affecting catecholaminergic neurotransmission might contribute to shape the individual response to antidepressants.",
keywords = "Antidepressant, COMT, Dopamine, Noradrenaline, Paroxetine, Serotonin",
author = "Francesco Benedetti and Cristina Colombo and Adele Pirovano and Elena Marino and Enrico Smeraldi",
year = "2009",
month = "3",
doi = "10.1007/s00213-008-1381-7",
language = "English",
volume = "203",
pages = "155--160",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting

AU - Benedetti, Francesco

AU - Colombo, Cristina

AU - Pirovano, Adele

AU - Marino, Elena

AU - Smeraldi, Enrico

PY - 2009/3

Y1 - 2009/3

N2 - Rationale: The noradrenergic and dopaminergic systems are targets for antidepressants and are stimulated by serotonergic antidepressant drugs. The COMT enzyme inactivates catecholamines, and the COMT Val(108/158)Met polymorphism (rs4680) influences the enzyme activity. Clinical studies on the effect of rs4680 on antidepressant response gave contrasting results. Objectives: We studied the effect of rs4680 on response to paroxetine antidepressant monotherapy at doses administered upon clinical need. Materials and methods: Fifty-five consecutively referred outpatients affected by a major depressive episode without psychotic features in course of major depressive disorder were administered paroxetine at a mean daily dose of 31.64 mg for 1 month. Changes in severity of depression were assessed with weekly Hamilton depression ratings and analyzed with repeated measures analysis of variance in the context of general linear model, taking into account potential confounding variables (age, sex, number of previous illness episodes, duration of current episode and paroxetine daily dose). Results: rs4680 significantly interacted with time in affecting antidepressant response to paroxetine, with outcome being inversely proportional to the enzyme activity: better effects in Met/Met homozygotes, worse effects in Val/Val homozygotes and intermediate effects in heterozygotes. The effect became significant at the third week of treatment. Paroxetine daily dose was proportional to baseline severity, but did not influence outcome. Conclusions: This is the first study that reports a positive effect of rs4680 on response to selective serotonin reuptake inhibitors monotherapy in a Caucasian sample. Our findings support the hypothesis that factors affecting catecholaminergic neurotransmission might contribute to shape the individual response to antidepressants.

AB - Rationale: The noradrenergic and dopaminergic systems are targets for antidepressants and are stimulated by serotonergic antidepressant drugs. The COMT enzyme inactivates catecholamines, and the COMT Val(108/158)Met polymorphism (rs4680) influences the enzyme activity. Clinical studies on the effect of rs4680 on antidepressant response gave contrasting results. Objectives: We studied the effect of rs4680 on response to paroxetine antidepressant monotherapy at doses administered upon clinical need. Materials and methods: Fifty-five consecutively referred outpatients affected by a major depressive episode without psychotic features in course of major depressive disorder were administered paroxetine at a mean daily dose of 31.64 mg for 1 month. Changes in severity of depression were assessed with weekly Hamilton depression ratings and analyzed with repeated measures analysis of variance in the context of general linear model, taking into account potential confounding variables (age, sex, number of previous illness episodes, duration of current episode and paroxetine daily dose). Results: rs4680 significantly interacted with time in affecting antidepressant response to paroxetine, with outcome being inversely proportional to the enzyme activity: better effects in Met/Met homozygotes, worse effects in Val/Val homozygotes and intermediate effects in heterozygotes. The effect became significant at the third week of treatment. Paroxetine daily dose was proportional to baseline severity, but did not influence outcome. Conclusions: This is the first study that reports a positive effect of rs4680 on response to selective serotonin reuptake inhibitors monotherapy in a Caucasian sample. Our findings support the hypothesis that factors affecting catecholaminergic neurotransmission might contribute to shape the individual response to antidepressants.

KW - Antidepressant

KW - COMT

KW - Dopamine

KW - Noradrenaline

KW - Paroxetine

KW - Serotonin

UR - http://www.scopus.com/inward/record.url?scp=60449108060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60449108060&partnerID=8YFLogxK

U2 - 10.1007/s00213-008-1381-7

DO - 10.1007/s00213-008-1381-7

M3 - Article

C2 - 18989660

AN - SCOPUS:60449108060

VL - 203

SP - 155

EP - 160

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 1

ER -